Novartis AG (NVS)
NYSE: NVS · IEX Real-Time Price · USD
+0.01 (0.01%)
At close: Jun 18, 2024, 4:00 PM
+0.01 (0.01%)
After-hours: Jun 18, 2024, 7:22 PM EDT

Company Description

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria.

The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG
Novartis AG logo
Country Switzerland
Founded 1895
IPO Date Nov 18, 1991
Industry Drug Manufacturers - General
Sector Healthcare
Employees 76,057
CEO Dr. Vasant Narasimhan M.D.

Contact Details

Lichtstrasse 35
Basel, V8 CH 4056
Phone 01141613241111

Stock Details

Ticker Symbol NVS
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001114448
CUSIP Number 66987V109
ISIN Number US66987V1098
SIC Code 2834

Key Executives

Name Position
Dr. Vasant Narasimhan M.D. Chief Executive Officer
Harry Kirsch Chief Financial Officer
Victor Bulto President of US
Dr. Patrick Horber M.D. President of International
Dr. Steffen Lang Ph.D. President of Operations
Paul Penepent Head of Group Financial Reporting and Accounting
Dr. Samir Shah M.D. Global Head of Investor Relations
Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk and Compliance Officer
Karen L. Hale Chief Legal Officer
Dr. Robert Kowalski Pharm.D. Chief People and Organization Officer

Latest SEC Filings

Date Type Title
May 31, 2024 SD Form - SD
May 22, 2024 144 Filing
Apr 23, 2024 6-K Report of foreign issuer
Feb 15, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Feb 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 6-K Report of foreign issuer
Jan 31, 2024 6-K Report of foreign issuer
Jan 31, 2024 IRANNOTICE Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012
Jan 31, 2024 20-F Annual and transition report of foreign private issuers
Jan 8, 2024 6-K Report of foreign issuer